Literature DB >> 8780527

APMA (4-aminophenylmercuric acetate) activation of stromelysin-1 involves protein interactions in addition to those with cysteine-75 in the propeptide.

G Galazka1, L J Windsor, H Birkedal-Hansen, J A Engler.   

Abstract

Matrix metalloproteinases (MMPs) can be activated in vitro by multiple mechanisms such as treatment with proteases, organomercurials, oxidants, and detergents. The proposed cysteine switch model for activation suggests that these multiple methods for activation cause the dissociation of the single cysteine residue in the propeptide from the active site zinc. In particular, it has been suggested that organomercurials such as 4-aminophenylmercuric acetate (APMA) work by directly reacting with the sulfhydryl group of this cysteine residue, resulting in its displacement from the active site. However, recent data by Chen et al. [(1993) Biochemistry 32, 10289-10295] demonstrated that modification of this cysteine residue in the propeptide of stromelysin-1 by sulfhydryl reagents did not result in an active enzyme as predicted. To investigate the roles that this cysteine residue and the propeptide salt bridge (R74 to D79) might play in the APMA-induced activation of stromelysin-1, we have changed these residues by site-directed mutagenesis. Wild-type stromelysin-1 and the mutants were all expressed at detectable levels using a recombinant vaccinia virus system and determined to be catalytically competent by zymography. The wild-type stromelysin-1 and the cysteine mutants (C75S and C75H) underwent APMA-induced activation as determined by the characteristic reduction in molecular weight associated with activation and by their ability to cleave casein only when activated. On the other hand, mutants R74K, D79A, and C75H/D79A did not undergo APMA-induced activation. These results demonstrate that APMA-induced activation of stromelysin-1 involves protein interactions in addition to those with cysteine-75 in the propeptide and also suggest that the R74 to D79 salt bridge may play a role.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8780527     DOI: 10.1021/bi960618e

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  15 in total

1.  Atheroma Niche-Responsive Nanocarriers for Immunotherapeutic Delivery.

Authors:  Erica B Peters; Nick D Tsihlis; Mark R Karver; Stacey M Chin; Bruno Musetti; Benjamin T Ledford; Edward M Bahnson; Samuel I Stupp; Melina R Kibbe
Journal:  Adv Healthc Mater       Date:  2019-01-08       Impact factor: 9.933

2.  Analysis of the trajectory of osteoarthritis development in a mouse model by serial near-infrared fluorescence imaging of matrix metalloproteinase activities.

Authors:  Averi A Leahy; Shadi A Esfahani; Andrea T Foote; Carrie K Hui; Roshni S Rainbow; Daisy S Nakamura; Brian H Tracey; Umar Mahmood; Li Zeng
Journal:  Arthritis Rheumatol       Date:  2015-02       Impact factor: 10.995

3.  MMP13 mutation causes spondyloepimetaphyseal dysplasia, Missouri type (SEMD(MO).

Authors:  Ann M Kennedy; Masaki Inada; Stephen M Krane; Paul T Christie; Brian Harding; Carlos López-Otín; Luis M Sánchez; Anna A J Pannett; Andrew Dearlove; Claire Hartley; Michael H Byrne; Anita A C Reed; M Andrew Nesbit; Michael P Whyte; Rajesh V Thakker
Journal:  J Clin Invest       Date:  2005-10       Impact factor: 14.808

Review 4.  The Role of ADAM17 in Inflammation-Related Atherosclerosis.

Authors:  Bai-Yi Tang; Jin Ge; Yang Wu; Juan Wen; Xiao-Hong Tang
Journal:  J Cardiovasc Transl Res       Date:  2022-06-01       Impact factor: 4.132

5.  Agonist-regulated cleavage of the extracellular domain of parathyroid hormone receptor type 1.

Authors:  Christoph Klenk; Stefan Schulz; Davide Calebiro; Martin J Lohse
Journal:  J Biol Chem       Date:  2010-01-15       Impact factor: 5.157

6.  The regulation of TACE catalytic function by its prodomain.

Authors:  Xiaoou Li; Yuan Yan; Wei Huang; Yuzhen Yang; Hongwei Wang; Liwen Chang
Journal:  Mol Biol Rep       Date:  2008-04-04       Impact factor: 2.316

7.  SH2B1beta (SH2-Bbeta) enhances expression of a subset of nerve growth factor-regulated genes important for neuronal differentiation including genes encoding urokinase plasminogen activator receptor and matrix metalloproteinase 3/10.

Authors:  Linyi Chen; Travis J Maures; Hui Jin; Jeffrey S Huo; Shafaat A Rabbani; Jessica Schwartz; Christin Carter-Su
Journal:  Mol Endocrinol       Date:  2007-10-18

8.  Expression, regulation and functional characterization of matrix metalloproteinase-3 of human trophoblast.

Authors:  H Husslein; S Haider; G Meinhardt; J Prast; S Sonderegger; M Knöfler
Journal:  Placenta       Date:  2009-01-19       Impact factor: 3.481

9.  Inhibition of aberrant tissue remodelling by mesenchymal stromal cells singly coated with soft gels presenting defined chemomechanical cues.

Authors:  Chandramohan R Tamatam; Ik Sung Cho; Sing Wan Wong; Peter T Toth; Raymond Bargi; Patrick Belvitch; James C Lee; Jalees Rehman; Sekhar P Reddy; Jae-Won Shin
Journal:  Nat Biomed Eng       Date:  2021-06-03       Impact factor: 25.671

10.  The study of the inhibition of the recombinant TACE prodomain to endotoxemia in mice.

Authors:  Xiaoou Li; Yuan Yan; Wei Huang; Yuzhen Yang
Journal:  Int J Mol Sci       Date:  2009-12-18       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.